Aytu's EXXUA Launch Shows Early Promise Amid Portfolio Transition

First-in-class MDD drug gains traction with 1,300+ scripts in first partial quarter, but financials still in transition

AYTU · Earnings Call · 2026-05-13

A Small-Cap Pivot to a First-in-Class MDD Drug

Aytu BioPharma is executing a pivot from its legacy ADHD and pediatric portfolios to a new CNS opportunity with the launch of EXXUA, the first and only selective serotonin 5-HT1A receptor agonist approved for major depressive disorder (MDD). The company's fiscal Q3 2026 call (period ended March 31, 2026) was dominated by early launch metrics, which management described as highly encouraging. The market cap is just ~$23M, and the stock has traded flat over the last 90 days (down ~7%), reflecting anticipation rather than euphoria. The launch is a company-unique event, distinct from the broad sector themes of AI and tariffs visible in the global keyword trajectory. The strategic shift is clear in the numbers. Total revenue dropped to $12.4M from $18.5M a year ago, driven by intentional de-emphasis of ADHD and pediatric products. The decline is expected and deliberate—management notes that the legacy business “does generate cash even at these levels” (“the legacy business continues to provide an important foundation as we transition the company towards the larger CNS opportunity” — Joshua Disbrow, Chief Executive Officer · 2026-05-13).

Launch Metrics Show Encouraging Traction

The core evidence of change is the early adoption of EXXUA. In Q3, more than 1,300 prescriptions were written, with monthly progression from ~200 in January to ~400 in February to over 700 in March. April continued the acceleration: “we saw over 920 prescriptions written, up from the 700 in March. That's a 26% month-over-month sequential growth rate” — Joshua Disbrow, Chief Executive Officer · 2026-05-13. Over 450 unique prescribers wrote the drug—10–13% of the initial target universe of 3,500–4,000. Unit sales hit 3,335 (1,807 30-count and 1,528 titration packs), translating to $2.4M in net revenue. Prescriptions written are the clearest measure of physician demand, and the company is also seeing early refill activity, a key proof point for durability.

Phrases from even difficult patients like "lifechanging" and a specific patient saying, "He has never felt this good in his entire life." are coming through at this point almost daily.
Joshua Disbrow, Chief Executive Officer · 2026-05-13

This traction is particularly notable given that only a partial quarter of full sales force deployment occurred—about a third of the 40+ reps only entered the field in March. Management emphasized that the launch is disciplined and focused on high-prescribing psychiatric practices, with reimbursement dynamics supporting the early momentum.

Reimbursement and Financial Realities

Reimbursement is critical for a specialty pharma launch, and early signs are positive. In the Q&A, Josh Disbrow noted that prior authorization approval rates exceed 70%: “over 70% of those are getting approved” (“we are seeing a very high rate... over 70% of those are getting approved” — Joshua Disbrow, Chief Executive Officer · 2026-05-13). The company's RxConnect platform is designed to remove friction, offering a no-cost 14-day titration pack and guaranteeing coverage for the first two months for commercially insured patients. This strategy intentionally pushes scripts ahead of net revenue in early months, but management expects normalization as patients move to refills. Financially, the quarter was a loss. Operating income came in at -$5.6M, versus -$1.7M in the prior year quarter, reflecting a $700K inventory write-down on Adzenys and increased sales/marketing spend. Gross margin fell to 61% from 69% (excluding the write-down, ~67%). Cash at quarter end was $26.7M, down from $30M, and total debt was $11.4M. The company also completed a warrant amendment that reduced derivative warrant liabilities and boosted equity by $26.4M, a positive balance-sheet event.

Comparison to Prior Calls and Outlook

The current call is consistent with prior guidance. In the February call, management had outlined a strategy to expand territories cautiously, and the current progress validates that plan. “we have identified territories beyond the 44... There will not be any appetite to raise capital in the context of that specific piece” — Josh Disbrow, Chief Executive Officer · 2026-02-03 from that call reiterates the disciplined approach. Similarly, the November call emphasized a “strict psychiatry play,” which is exactly the focus being executed today (“we will be hyper focused. As we've said in the past, this will be a strict psychiatry play” — Joshua Disbrow, Chief Executive Officer · 2025-11-13). EXXUA launch is the central theme, and it remains early. The company is not providing formal guidance but expects mid-to-high 60% gross margins over time and a near-term path to profitability as EXXUA scales. The legacy ADHD and pediatric portfolios are intentionally de-emphasized—the legacy portfolios are still cash-generative but declining. The stock's recent stability (90d return -7.1%, drawdown -9.9% from a $2.63 peak) suggests the market is waiting for more proof. If the launch continues at this pace, Aytu could become a meaningful player in the MDD space, but the tiny market cap and elevated risk warrant caution.